AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie alphagan/Combigan (brimonidine) — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2025
54
Period ended Dec 31, 2025
Change on a year earlier
-30.8%
78 in Q4 2024
History
27 quarters
Since Q2 2019
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up alphagan/combigan (brimonidine) — worldwide net revenues ($m)
- Alphagan/Combigan (brimonidine) — U.S. net revenues ($M)18 · Q4 2025
- Alphagan/Combigan (brimonidine) — International net revenues ($M)36 · Q4 2025
- Alphagan/Combigan (brimonidine) — Worldwide reported growth YoY (%)-30.5% · Q4 2025
- Alphagan/Combigan (brimonidine) — Worldwide operational (constant-currency) growth YoY (%)-30.9% · Q4 2025
Cite this data
StockData. (2026). AbbVie Alphagan/Combigan (brimonidine) — Worldwide net revenues ($M) ($M), quarterly Q2 2019–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/alphagan_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.